Preprint servers and peer-reviewed journals are seeing surging audiences, with many new readers not well versed in the limitations of the latest research findings. From a report: Early on Feb. 1, John Inglis picked up his phone and checked Twitter, as he does most mornings. He was shocked at what fresh hell awaited. Since 2013, Dr. Inglis, executive director of Cold Spring Harbor Laboratory Press in New York, has been helping manage a website called bioRxiv, pronounced "bio archive." The site's goal: improve communication between scientists by allowing them to share promising findings months before their research has gone through protracted peer review and official publication. But the mess he was seeing on Twitter suggested a downside of the service provided by the site, known as a preprint server, during the emerging coronavirus pandemic. The social media platform was awash with conspiracy theories positing that the new coronavirus had been engineered by the Chinese government for population control. And the theorists' latest evidence was a freshly submitted paper on bioRxiv from a team of Indian researchers that suggested an "uncanny similarity" between proteins in H.I.V. and the new virus.

Traditionally, the Indian researchers would have submitted a paper to a peer-reviewed journal, and their manuscript would be scrutinized by other scientists. But that process takes months, if not more than a year. BioRxiv, medRxiv -- another site co-founded by Dr. Inglis -- and other preprint servers function as temporary homes that freely disseminate new findings. For scientists on the front lines of the coronavirus response, early glimpses at others' research helps with study of the virus. But there is a growing audience for these papers that are not yet fully baked, and those readers may not understand the studies' limitations. Views and downloads on medRxiv, for instance, have increased more than 100-fold since December, Dr. Inglis says. People with little scientific training, or none at all, are desperate for new knowledge to better inform their day-to-day decisions. The news media wants to keep readers and viewers updated with the latest developments. And agents of disinformation seek to fuel conspiratorial narratives.

Verily, the Alphabet life sciences division that launched its COVID-19 screening and testing program last month, is still under scrutiny from lawmakers over how it is collecting users' data, as well as its plans to expand its test sites outside of California. From a report: At the end of March, five US senators wrote to Verily asking, among several other things, whether its screening website was compliant with the HIPAA Privacy Rule, and whether Verily intended to remove the requirement that all users who screen for COVID-19 have a Google account. Verily has now addressed those questions in a letter sent to the same senators and obtained by Business Insider. In it, Verily assured the senators that any data collected wouldn't be used for commercial purposes or sold to third parties. But it also confirmed that its screening site was not in compliance with the HIPAA privacy rule.

"Verily has focused on the protection of the security and privacy of personal health information since the inception of its Baseline COVID-19 Program," the company wrote. "With respect to its Baseline COVID-19 Program, Verily is not acting as a covered entity or a business associate as defined by HIPAA. As the Program expands, we will continue to prioritize the protection of individual health data. However, in the future if we engage in a program where we do become a covered entity or we are required to sign a BAA we will take all the appropriate steps to ensure compliance with HIPAA."

Nectar Gan, Caitlin Hu and Ivan Watson, reporting for CNN: China has imposed restrictions on the publication of academic research on the origins of the novel coronavirus, according to a central government directive and online notices published by two Chinese universities, that have since been removed from the web. Under the new policy, all academic papers on Covid-19 will be subject to extra vetting before being submitted for publication. Studies on the origin of the virus will receive extra scrutiny and must be approved by central government officials, according to the now-deleted posts.

A medical expert in Hong Kong who collaborated with mainland researchers to publish a clinical analysis of Covid-19 cases in an international medical journal said his work did not undergo such vetting in February. The increased scrutiny appears to be the latest effort by the Chinese government to control the narrative on the origins of the coronavirus pandemic, which has claimed more than 100,000 lives and sickened 1.7 million people worldwide since it first broke out in the Chinese city of Wuhan in December. Since late January, Chinese researchers have published a series of Covid-19 studies in influential international medical journals.

Researchers have developed a nasal Alzheimer's vaccine that was successful in reducing atrophied brain matter in mice by blocking a protein that causes the disease. It also reduced changes and abnormal behavior in the brain normally associated with the disease. The study was published in the journal Nature. Interesting Engineering reports: "Much more research is necessary for the vaccine to be used in humans, but it is an accomplishment that can contribute to the development of a dementia cure," team member Haruhisa Inoue, a professor at Kyoto University, told The Asahi Shimbun. Alzheimer's disease and other forms of dementia are characterized by an abnormal accumulation of tau proteins in the brain. In the study, the research team incorporated a gene into a harmless virus to make it produce tau.

They then administered the virus nasally to mice with genes that made them prone to developing dementia. The vaccine proceeded to stimulate the mice's immune system, causing them to build antibodies that removed the tau proteins. These antibodies were more than double in mice who had the vaccine administered compared to those that did not. In addition, the vaccinated mice's brain areas were only two-thirds as atrophied as those who were not vaccinated. Finally, no detrimental side effects were recorded during the eight months the scientists observed the mice.

There are 70 coronavirus vaccines in development globally, with three candidates already being tested in human trials, according to the World Health Organization, as drugmakers race to find a cure for the deadly pathogen. From a report: The furthest along in the clinical process is an experimental vaccine developed by Hong Kong-listed CanSino Biologics and the Beijing Institute of Biotechnology, which is in phase 2. The other two being tested in humans are treatments developed separately by U.S. drugmakers Moderna and Inovio Pharmaceuticals, according to a WHO document. Progress is occurring at unprecedented speed in developing vaccines as the infectious pathogen looks unlikely to be stamped out through containment measures alone. The drug industry is hoping to compress the time it takes to get a vaccine to market -- usually about 10 to 15 years -- to within the next year.

The UK public will soon be able to find out if they may have been in the vicinity of people unwell with coronavirus via a new contact-tracing app, Matt Hancock, the health secretary, has said. From a report: At No 10's daily press conference on Sunday, Hancock said the NHS app would allow people to report their symptoms, and then the app would anonymously alert other app users that had been in contact with that person in recent days. The Guardian reported last week that the app, developed by NHSX -- the health service's digital transformation arm -- with academic and industry partners, is in the advanced stages of evaluation and is weeks away from being ready to be deployed. About 60% of the adult population would need to sign up and engage with the app by registering their symptoms or positive test results for it to be effective. Their proximity to other users would be logged, and they would follow advice given in alerts to self-isolate -- even in cases where they were not aware of having been in contact with someone infected.

A team in Colombia is to test a ventilator made with a Raspberry Pi computer and easy-to-source parts. From a report: The design and computer code were posted online in March by a man in California, who had no prior experience at creating medical equipment. Marco Mascorro, a robotics engineer, said he built the ventilator because knew the machines were in high demand to treat Covid-19. His post prompted a flood of feedback from healthcare workers. He has used the advice to make improvements. "I am a true believer that technology can solve a lot of the problems we have right now specifically in this pandemic," he told the BBC. The Colombian team said the design was important for their South American country because parts for traditional models could be hard to obtain. By contrast, Mr Mascorro's design uses only easy-to-find parts -- for example, the valves it employs can commonly be found at car and plumbing supply stores. The machine is set to be put through a fast-tracked round of tests at two institutions in Bogota -- the University Hospital of the Pontifical Xavierian University and Los Andes University.

Yahoo News shares an encouraging report from former Newsweek correspondent Andrew Romano: Until very recently, nationwide data about how many COVID-19 patients are currently receiving treatment in hospitals was hard to come by. It's still incomplete and inconsistent. But on April 7, researchers at the University of Minnesota launched the U.S. COVID-19 Hospitalization Tracking Project, which is just what it sounds like: the first effort to capture, track, visualize and compare daily data on the number of COVID-19 hospitalizations from the 37 state departments of health that are reporting this information (so far).

The reason this information is so valuable is simple. Because hospitalization typically occurs a week or so after infection, it's less of a lagging indicator than the death count (which trails by two to two and a half weeks) and more directly tied to the trajectory of the epidemic than the testing-dependent case count. It's also a measure of the most pressing public health concern of all: how close we are to exceeding the capacity of our hospital system, which can make COVID-19 much deadlier than it would otherwise be.

Which brings us to New York and California. Chart each state's hospitalization data over the last seven days or so, and two different narratives emerge. Both are encouraging...

On Wednesday, New York's daily death count hit an all-time high: 799. But that reflects infections from weeks ago, before the state's lockdown started. The number of people testing positive stayed relatively flat. Meanwhile, there were fewer new hospitalizations — just 200 — than on any day since March 18. It wasn't a blip. The amount of new daily hospitalizations has been declining since last Thursday: from 1,427 on April 2 to 1,095 on April 3 to 656 on April 6 to 200 on April 8. (There are some questions about inconsistencies between the data from New York state and New York City, but the trend line is the same.) Previously, the total current number of coronavirus patients in New York hospitals had been increasing by at least 20 percent a day for weeks. Now the overall number of hospitalizations is barely increasing at all...

The good news in New York is that the state might be peaking now. The good news in California is that the state might not peak for a long time — but its path to that peak will be so incremental, its curve so flat, that coronavirus patients will never come close to overwhelming the hospital system.
The numbers do look encouraging. (Click on the "Currently Hospitalized" rectangle and then select each state's two-letter abbreviation from the dropdown menu.) In fact, the San Francisco Bay Area recorded its fourth day of declining ICU patients on Saturday. "Home-sheltering efforts may well be paying off, at least according to the number of hospitalizations and patients in ICU," reports the Bay Area Newsgroup.

And SFGate noted Friday that the statewide hospitalization figures "have also been relatively flat in recent days, with Governor Gavin Newsom expressing guarded optimism after the number of individuals in intensive care units decreased Thursday."

This week the Washington Post asked their "business of health care" reporter to explain the true status in the scientific community of hydroxychloroquine, an already-approved malaria drug also used to control inflammation in lupus and rheumatoid arthritis patients.

"There is no clear evidence that the drugs work against the coronavirus," he writes, "despite their use by hospitals and doctors in the United States and other countries since the outbreak began." Their antiviral properties have been proved in test tubes, but rigorous clinical trials to test their effectiveness in humans have not been completed. Limited studies on coronavirus patients have been published by researchers in France and China, but their extremely small size and other problems prevented them from being statistically significant. The French study included a combination of hydroxychloroquine with the antibiotic azithromycin that showed benefit in six patients... Another study in 11 patients in France showed no evidence the regimen works. A Chinese study also showed no benefit over the standard course of treatment.

Mainstream scientists caution against using the drugs without more evidence they are effective... The dangerous side effects of the drugs are much better known. Most seriously, the drugs can trigger arrhythmia, which can lead to a fatal heart attack in patients with cardiovascular disease or who are taking certain drugs, including anti-depression medications. Doctors recommend screening with an electrocardiogram to prevent the drug from being given to the 1 percent of patients at the greatest risk of a cardiac event. The drugs also can cause vision loss called retinopathy with long-term use, and chloroquine has been associated with psychosis...

As the coronavirus has spread from China across the world and to the United States, the dire reality is that there is no vaccine and no approved drug available to treat the serious respiratory symptoms that are claiming thousand of lives.
Long-time Slashdot reader UnknowingFool shares doubts raised about that small French study, as even its publisher now acknowledges it "does not meet" their own expected standards.

The Post does note that multiple trials are "ongoing" (though six different research centers testing the drug told CNN it would be "months" before results were known). But the Post adds that already "public and political interest has caused runs, hoarding and severe shortages in recent weeks."

An anonymous reader quotes Reuters: U.S. deaths due to the coronavirus surpassed 20,000 on Saturday, the highest reported number in the world, according to a Reuters tally, although there are signs the pandemic might be nearing a peak. Italy has the second most reported deaths at 19,468 and Spain is in third place with 16,353.

The United States has five times the population of Italy and nearly seven times the population of Spain.

The United States has seen its highest death tolls to date in the epidemic with roughly 2,000 deaths a day reported for the last four days in a row.
While America has 4.3% of the world's population, it appears to have nearly 20% of the world's 100,000 confirmed fatalities from COVID-19. [Update: This comparison might be skewed by countries underreporting their fatalities.] Long-time blogger Jason Kottke notes the virus is now causing more deaths per day in the U.S. than any other cause, including heart disease and cancer.

But earlier this week Kottke also shared graphs from six different countries visualizing positive new statistics from the Imperial College team suggesting social distancing has worked in 11 European countries they analyzed.

"We estimate that interventions across all 11 countries will have averted 59,000 deaths up to 31 March," the researchers write, adding "Many more deaths will be averted through ensuring that interventions remain in place until transmission drops to low levels."

RadioShack's former CEO tells Canada's National Post newspaper the surprising story of what happened after he left the company in 2004: When it came, rather than being crestfallen, he felt liberated, and free to pursue an "itch" that he had always felt the need to scratch. So he applied to medical school at McMaster University in Hamilton, Ontario... "I don't miss being a CEO one bit," Levy says. "I enjoyed it immensely, when I was doing it. But do I enjoy what I am doing now? The answer is, immensely."

Brian Levy, MD, was talking about his unusual career path with a reporter, via a socially-distanced phone call, on an April afternoon after wrapping up an overnight shift in the Emergency Department at Brampton Civic Hospital, northwest of Toronto. Brampton Civic is among the busiest emergency departments in Canada. The former CEO initially fancied becoming a psychiatrist, given all his years managing people, but he realized early on in medical school that he was more of a generalist, not to mention a Type-A, adrenaline-junky.

"Emergency medicine is a perfect fit for my personality," he says.
The article notes Levy's department "is eerily quiet, preparing for an expected surge in COVID-19 cases" -- and that in his spare time he's still an electronics geek.

"I am just one of those people who was very fortunate, where things worked out, and where I could do not just do one thing I really enjoyed in life, but two."

The New York Post reports that a COVID-19 vaccine "may be six months away, according to a researcher leading a team of scientists in England." "I think there's a high chance that it will work based on other things that we have done with this type of vaccine," Sarah Gilbert, a professor of virology at Oxford told The Times of London. "It's not just a hunch and as every week goes by we have more data to look at. I would go for 80 percent, that's my personal view."
Gilbert added that if they can find places that haven't imposed a lockdown, "we will get our efficacy results very quickly."

America and Israel have also reported encouraging progress on a vaccine. And in the Netherlands and Australia, researchers are testing the effectiveness of the BCG tuberculosis vaccine developed in the 1920s (with more tests being scheduled for Africa, and experiments in the U.K.) UPI reports researchers in the Netherlands "have started recruiting 1,000 healthcare workers, who are at high risk for COVID-19, in eight hospitals who will receive either the BCG vaccine or a placebo."

The Times of London reports that the U.K. government "signalled that it would be willing to fund the manufacture of millions of doses in advance" if the results of professor Gilbert's research looked promising. "This would allow it to be available immediately to the public if it were proven to work.

"With ministers struggling to find a strategy to exit the lockdown, long-term hopes of a return to normality rely on a vaccine."

hackingbear writes: After testing blood from 500 residents for antibodies to the COVID-19 virus in the town of Gangelt, which is a hot spot of the pandemic in Germany, scientists at a nearby university say they have determined that 14% have been infected and are therefore "immune." Some of those people would have had no symptoms at all. Scientists found that 2% of residents were actively infected by the coronavirus and a total of 14% had antibodies, indicating a prior infection. "From the result of their blood survey, the German team estimated the death rate in the municipality at 0.37% overall, a figure significantly lower than what's shown on a dashboard maintained by Johns Hopkins, where the death rate in Germany among reported cases is 2%," reports MIT Technology Review. In contrast, the 2019-2020 seasonal flu has infected up to 17% of U.S. population and killed ~0.1% of those infected. Since first emerged in late December, or purportedly as early as late November, the COVID-19 has infected over 1.6 million people and killed over 100,000.

wiredmikey writes from a report via SecurityWeek: Authorities in Italy are using Drones equipped with heat sensors to take the temperature of citizens and send the information to a drone operator, who has a thermal map on his hand-held screen -- shining orange and purple blobs. The hovering drone emits a mechanical buzz reminiscent of a wasp and shouts down instructions in a tinny voice. "Attention! You are in a prohibited area. Get out immediately," commands the drone, about the size of a loaf of bread. "Violations of the regulations result in administrative and criminal penalties," the drone says. "Once a person's temperature is read by the drone, you must still stop that person and measure their temperature with a normal thermometer," Matteo Copia, a police commander, said. Copia says the local police force has received new powers that allow it to check people's temperature without their knowledge or permission.

The number of deaths linked to the coronavirus worldwide has passed 100,000 as known infections surged past 1.6 million, according to data collected by The New York Times. From a report: At least 177 countries have reported cases. The most recent was war-torn Yemen, which reported its first coronavirus case on Friday. The death toll in the United States has surpassed that of Spain, with almost 18,000 fatalities related to the virus reported by Friday afternoon. Only Italy has reported more deaths. Although some governments are considering easing restrictions, lockdowns are being extended across much of the world heading into the Easter weekend, and policing measures stepped up. Tokyo's governor parted ways with Japan's national government by requesting the closure of a range of businesses -- including nightclubs, karaoke bars, gyms and movie theaters -- during a state of emergency declared this week.

Engineering teams at Apple and Google have banded together to create a decentralized contact tracing tool that will help individuals determine whether they have been exposed to someone with COVID-19. From a report: Contact tracing is a useful tool that helps public health authorities track the spread of the disease and inform the potentially exposed so that they can get tested. It does this by identifying and 'following up with' people who have come into contact with a COVID-19 affected person. The first phase of the project is an API that public health agencies can integrate into their own apps. The next phase is a system level contact tracing system that will work across iOS and Android devices on an opt-in basis. The system uses on-board radios on your device to transmit an anonymous ID over short ranges -- using Bluetooth beaconing. Servers relay your last 14 days of rotating IDs to other devices which search for a match. A match is determined based on a threshold of time spent and distance maintained between two devices.

An anonymous reader quotes a report from Motherboard: A global group of scientists and lawyers announced their efforts to make their intellectual property free for use by others working on coronavirus pandemic relief efforts -- and urged others to do the same -- as part of the "Open Covid Pledge." Mozilla, Creative Commons, and Intel are among the founding members of this effort; Intel contributed to the pledge by opening up its portfolio of over 72,000 patents, according to a press release. Participants are asked to publicly take the pledge by announcing it on their own websites and issuing a press release.

"Immediate action is required to halt the COVID-19 Pandemic and treat those it has affected," the pledge states. "It is a practical and moral imperative that every tool we have at our disposal be applied to develop and deploy technologies on a massive scale without impediment. We therefore pledge to make our intellectual property available free of charge for use in ending the COVID-19 pandemic and minimizing the impact of the disease." From there, people and companies are asked to adopt a license detailing the terms and conditions their intellectual property will be available; while pledgers are permitted to write their own license based on their needs, the organizers wrote "Open COVID License 1.0" as a template for immediate use, which grants usage rights to anyone working toward "minimizing the impact of the disease, including without limitation the diagnosis, prevention, containment, and treatment of the COVID-19 Pandemic." The license is effective until one year after the World Health Organization declares the pandemic to be over. Other participants include Berkeley and UCSF's Innovative Genomics Institute, Fabricatorz Foundation, and United Patents.

jmcbain writes: In many societies, handshakes are a gesture of friendliness. How many times have you shaken hands when meeting new engineering professionals? Probably quite a lot. However, given what we've seen with the SARS-CoV-2 coronavirus, it's time for a new way to greet people. According to a CNBC article, Anthony Fauci, the head advisor of the USA's task force on the coronavirus, says "I don't think we should ever shake hands ever again, to be honest with you. Not only would it be good to prevent coronavirus disease, it probably would decrease instances of influenza dramatically in this country." Other scientists agree with Fauci. Gregory Poland, director of the Mayo Clinic Vaccine Research Group has been trying to put an end to handshakes for nearly three decades. He suggests tilting or bowing your head to greet another person like people did many decades ago. "When men greeted other people [back in the day], they raised tor tipped their hat," he says. Bruce Farber, chief of infectious diseases at Northwell Health in New York, thinks Americans need to start implementing other ways to great each other "like [with] a head bob or wave of a hand. This act would maintain proper distance, avoid contact and potential spread of COVID-19," Farber says.

Peter Pitts, former FDA associate commissioner, says shaking hands transmits germs and viruses "as swiftly as kissing and hugging" and until we develop a vaccine against COVID-19, the new normal will have to be "verbal greetings and long-sleeved elbow bumps." He adds: "The social theme song for right now is 'I wanna, but better not, hold your hand.' Love doesn't conquer all."

Foxconn's Wisconsin plant, the controversial recipient of billions of dollars in tax subsidies and the focus of several investigations, will produce ventilators with medical device firm Medtronic. From a report: The partnership was announced by Medtronic CEO Omar Ishrak in an interview with CNBC, who said that Foxconn will be manufacturing ventilators based on its PB-560 design in the next four to six weeks. Foxconn's Wisconsin plant was first announced way back in 2017 as a $10 billion LCD factory. It was labeled the "eighth wonder of the world" by President Trump, but Foxconn's plans for the site appear to have changed repeatedly over the years. At various points, Foxconn has said that it would build a smaller LCD factory, no factory at all, or that it would produce other items like a robot coffee kiosk. Now, it appears the factory will, in part at least, produce ventilators, after its planned opening next month.

Tekla Perry writes: In 2001, a rapid, easy-to-use, PCR-based testing system for biological testing was still in prototype form when letters containing anthrax spores started arriving in the mailboxes of journalists and senators. Its creators at startup Cepheid quickly adapted it to test for anthrax, and now it is used to run that test as part of U.S. mail sorting systems. The tool, now called GeneXpert, is also installed in health care facilities around the world. And cartridges to allow these systems to test for COVID-19 -- the first rapid such test approved in the U.S. -- are rolling out. The technology relies on microfluidics, and takes about 45 minutes to run an extremely accurate and sensitive test. Cepheid co-founder Kurt Petersen, now an angel investor, explains how it works. "The test cartridge contains microfluidic channels; these are made out of plastic using high-precision injection molding," explains Petersen. "All the chemicals needed for the process are stored in chambers within the system. In the center of the cartridge, a rotary valve turns to open different pathways, while a tiny plunger -- like a syringe -- moves fluids in and out as needed.

So, the plunger pulls the sample into the center, the valve rotates, and the plunger pushes it into another region of the cartridge to do an operation on it. The system can do that multiple times, moving the sample to different regions with different chemicals, extracting RNA, mixing it with the reverse transcriptase that synthesizes complementary DNA that matches the RNA, and eventually pushing it into PCR reaction tube, where rapid heating and cooling speeds up the process of copying the DNA. Each new copy of the DNA gets a fluorescent molecule attached, which allows an optical system to determine whether or not the targeted gene sequence is in the sample."